From: The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
Study | Region | Tumor type | Sample size | TNM stage | FAM83H-AS1 expression | Cut-off value | Detection method | Outcome measure | NOS | |
---|---|---|---|---|---|---|---|---|---|---|
High | Low | |||||||||
Arnes et al. [13] | United States | PDAC | 49 | NA | 25 | 24 | Median | qRT-PCR | OS | 5 |
Baratieh et al. [14] | Iran | GC | 74 | I–IV | 37 | 37 | Median | qRT-PCR | OS | 7 |
BRCA | 382 | NA | 191 | 191 | Median | qRT-PCR | OS | 5 | ||
KIRP | 72 | NA | 36 | 36 | Median | qRT-PCR | OS | 5 | ||
OC | 184 | NA | 92 | 92 | Median | qRT-PCR | OS | 5 | ||
Bi et al. [9] | China | Glioma | 187 | I–IV | 29 | 19 | Median | qRT-PCR | OS | 7 |
Da et al. [7] | China | GC | 107 | I–IV | 53 | 54 | Median | qRT-PCR | OS, DFS | 7 |
Dou et al. [16] | China | OC | 80 | I–IV | 38 | 42 | Median | qRT-PCR | OS | 7 |
Gong et al. [8] | China | OC | 100 | I–IV | 48 | 52 | Median | qRT-PCR | OS | 7 |
Lu et al. [18] | China | CRC | 62 | I–IV | 31 | 31 | Median | qRT-PCR | OS | 7 |
Ma et al. [21] | China | HCC | 66 | I–IV | 32 | 34 | Median | qRT-PCR | OS | 7 |
Shan et al. [10] | China | BLCA | 96 | I–IV | 48 | 48 | Median | qRT-PCR | OS | 7 |
Wang et al. [15] | China | GC | 168 | NA | 84 | 84 | Median | qRT-PCR | NA | 6 |
Yang et al. [32] | China | CRC | 87 | I–IV | 51 | 36 | Median | qRT-PCR | OS | 7 |
Yang et al. [17] | China | BRCA | 837 | I–IV | 419 | 418 | Median | qRT-PCR | OS | 7 |
Yang et al. [19] | China | CRC | 166 | NA | 83 | 83 | Median | qRT-PCR | OS | 5 |
Zhang et al. [20] | China | LC | 101 | I–III | 51 | 50 | Median | qRT-PCR | OS | 7 |